Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 540

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

Open access
Eleveld, Thomas F, Oldridge, Derek A, Bernard, Virginie, Koster, Jan, Daage, Leo Colmet, Diskin, Sharon J, Schild, Linda, Bentahar, Nadia Bessoltane, Bellini, Angela, Chicard, Mathieu, Lapouble, Eve, Combaret, Valérie, Legoix-Né, Patricia, Michon, Jean, Pugh, Trevor J, Hart, Lori S, Rader, JulieAnn, Attiyeh, Edward F, Wei, Jun S, Zhang, Shile, Naranjo, Arlene, Gastier-Foster, Julie M, Hogarty, Michael D, Asgharzadeh, Shahab, Smith, Malcolm A, Guidry Auvil, Jaime M, Watkins, Thomas B K, Zwijnenburg, Danny A, Ebus, Marli E, van Sluis, Peter, Hakkert, Anne, van Wezel, Esther, van der Schoot, C Ellen, Westerhout, Ellen M, Schulte, Johannes H, Tytgat, Godelieve A, Dolman, M Emmy M, Janoueix-Lerosey, Isabelle, Gerhard, Daniela S, Caron, Huib N, Delattre, Olivier, Khan, Javed, Versteeg, Rogier, Schleiermacher, Gudrun, Molenaar, Jan J, Maris, John M·2015·Nature Genetics

Abstract

The majority of patients with neuroblastoma have tumors that initially respond to chemotherapy, but a large proportion will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole-genome sequencing of 23 paired diagnostic and relapse neuroblastomas showed clonal evolution from the diagnostic tumor, with a median of 29 somatic mutations unique to the relapse sample. Eighteen of the 23 relapse tumors (78%) showed mutations predicted to activate the RAS-MAPK pathway. Seven of these events were detected only in the relapse tumor, whereas the others showed clonal enrichment. In neuroblastoma cell lines, we also detected a high frequency of activating mutations in the RAS-MAPK pathway (11/18; 61%), and these lesions predicted sensitivity to MEK inhibition in vitro and in vivo. Our findings provide a rationale for genetic characterization of relapse neuroblastomas and show that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ng.3333

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 540

Metadata

Authors
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T. J., Hart, L. S., Rader, J., Attiyeh, E. F., Wei, J. S., Zhang, S., Naranjo, A., Gastier-Foster, J. M., Hogarty, M. D., Asgharzadeh, S., Smith, M. A., Guidry Auvil, J. M., Watkins, T. B. K., Zwijnenburg, D. A., Ebus, M. E., van Sluis, P., Hakkert, A., van Wezel, E., van der Schoot, C. E., Westerhout, E. M., Schulte, J. H., Tytgat, G. A., Dolman, M. E. M., Janoueix-Lerosey, I., Gerhard, D. S., Caron, H. N., Delattre, O., Khan, J., Versteeg, R., Schleiermacher, G., Molenaar, J. J., & Maris, J. M.
Venue
Nature Genetics
Published
2015-06-29
Volume
47
Issue
8
Pages
864-871
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2213548494
Cited by
540
References
41
FWCI
32.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. https://app.cochat.ai/papers/10.1038/ng.3333
The paper
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Daage, L. C., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T. J., Hart, L. S., Rader, J., Attiyeh, E. F., Wei, J. S., . . . Maris, J. M. (2015). Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics. https://doi.org/10.1038/ng.3333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.